News
ICON Reports First Quarter 2025 ResultsInvestor Relations +1 888 381 7923 Nigel Clerkin Chief Financial Officer +353 1 291 2000 Kate Haven Vice President Investor Relations +1 888 381 7923 http ...
In 2024, ICON supported over 1,270 clinical studies involving over 416,000 patients. Our efforts contributed to 19 medicines receiving original or supplemental approval.
ICON's revenues and net income have increased by 196.06% and 137.71%, respectively, between 2020 and 2024. Even though the CRO market expects a challenging outlook for 2025, in the next 9–10 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback